{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:43:45Z","timestamp":1789145025377,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.vaccine.2015.11.048","type":"journal-article","created":{"date-parts":[[2015,11,29]],"date-time":"2015-11-29T08:00:31Z","timestamp":1448784031000},"page":"334-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands"],"prefix":"10.1016","volume":"34","author":[{"given":"Gertjan H.J.","family":"Wagenvoort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Vlaminckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Rozenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2015.11.048_bib0185","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3201\/eid1811.120329","article-title":"Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, The Netherlands","volume":"18","author":"van Deursen","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"9693","key":"10.1016\/j.vaccine.2015.11.048_bib0190","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O\u2019Brien","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2015.11.048_bib0195","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/infdis\/jis240","article-title":"Aging population and future burden of pneumococcal pneumonia in the United States","volume":"205","author":"Wroe","year":"2012","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2015.11.048_bib0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/431521","article-title":"The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults","volume":"192","author":"Kyaw","year":"2005","journal-title":"J Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2015.11.048_bib0205","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1016\/j.vaccine.2015.06.062","article-title":"Impact of PCV7\/PCV13 introduction on community-acquired alveolar pneumonia in children <5 Years","volume":"33","author":"Greenberg","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.048_bib0210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12325-013-0007-6","article-title":"The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review","volume":"30","author":"Myint","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2015.11.048_bib0215","first-page":"CD000422","article-title":"Vaccines for preventing pneumococcal infection in adults","volume":"1","author":"Moberley","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2015.11.048_bib0220","series-title":"Pneumococcal vaccine in elderly adults and risk groups","author":"Knottnerus","year":"2003"},{"issue":"26","key":"10.1016\/j.vaccine.2015.11.048_bib0225","first-page":"1454","article-title":"Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk","volume":"151","author":"de Greeff","year":"2007","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"8","key":"10.1016\/j.vaccine.2015.11.048_bib0230","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.clinthera.2010.06.016","article-title":"Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged >or =65 years in The Netherlands","volume":"32","author":"Rozenbaum","year":"2010","journal-title":"Clin Ther"},{"issue":"18","key":"10.1016\/j.vaccine.2015.11.048_bib0235","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.vaccine.2014.02.008","article-title":"Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?","volume":"32","author":"Weil-Olivier","year":"2014","journal-title":"Vaccine"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2015.11.048_bib0240","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0264-410X(01)00347-4","article-title":"Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and\/or 23-valent polysaccharide vaccine among HIV-infected adults","volume":"20","author":"Feikin","year":"2001","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.11.048_bib0245","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.048_bib0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jinf.2012.02.017","article-title":"The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England","volume":"65","author":"van Hoek","year":"2012","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.048_bib0255","doi-asserted-by":"crossref","first-page":"ofu024","DOI":"10.1093\/ofid\/ofu024","article-title":"Rates of pneumococcal disease in adults with chronic medical conditions","volume":"1","author":"Shea","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.11.048_bib0260","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1086\/600045","article-title":"Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome","volume":"49","author":"Jansen","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.048_bib0265","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3201\/eid1605.091223","article-title":"Effects of pneumococcal conjugate vaccine 2 years after its introduction, The Netherlands","volume":"16","author":"Rodenburg","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2015.11.048_bib0270","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3201\/eid2111.140780","article-title":"Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, The Netherlands","volume":"21","author":"Knol","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2015.11.048_bib0275","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.vaccine.2004.02.017","article-title":"Vaccination of high-risk patients against influenza: impact on primary care contact rates during epidemics. Analysis of routinely collected data","volume":"22","author":"Tacken","year":"2004","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2015.11.048_bib0280","first-page":"A3109","article-title":"Increased multimorbidity in patients in general practice in the period 2003\u20132009","volume":"155","author":"Tacken","year":"2011","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.vaccine.2015.11.048_bib0285","series-title":"Modern Epidemiology","first-page":"258","article-title":"Chapter 15 introduction to stratified analysis","author":"Rothman","year":"2008"},{"key":"10.1016\/j.vaccine.2015.11.048_bib0290","first-page":"433","article-title":"Frailty syndrome: an overview","volume":"9","author":"Chen","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.048_bib0295","doi-asserted-by":"crossref","first-page":"e94578","DOI":"10.1371\/journal.pone.0094578","article-title":"A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly","volume":"9","author":"Macintyre","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2015.11.048_bib0300","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1681\/ASN.2008080860","article-title":"Prediction, progression, and outcomes of chronic kidney disease in older adults","volume":"20","author":"Anderson","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.048_bib0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/fmb.11.146","article-title":"What is different about serotype 1 pneumococci?","volume":"7","author":"Ritchie","year":"2012","journal-title":"Future Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.11.048_bib0310","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1086\/499242","article-title":"Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen","volume":"42","author":"Sjostrom","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2015.11.048_bib0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3201\/eid1901.120741","article-title":"Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales","volume":"19","author":"Ladhani","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2015.11.048_bib0320","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1086\/423820","article-title":"Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children","volume":"190","author":"Brueggemann","year":"2004","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.048_bib0325","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.vaccine.2015.11.048_bib0330","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/518149","article-title":"Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine","volume":"44","author":"Albrich","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.11.048_bib0335","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.4161\/hv.24688","article-title":"The evidence for use of pneumococcal conjugate over polysaccharide in children","volume":"9","author":"Borrow","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2015.11.048_bib0340","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2015.11.048_bib0345","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.vaccine.2015.01.030","article-title":"Early impact of PCV7\/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study","volume":"33","author":"Regev-Yochay","year":"2015","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2015.11.048_bib0350","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM200003093421002","article-title":"Cigarette smoking and invasive pneumococcal disease, Active Bacterial Core Surveillance Team","volume":"342","author":"Nuorti","year":"2000","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2015.11.048_bib0355","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1017\/S0950268813002860","article-title":"Increased incidence of serotype-1 invasive pneumococcal disease in young female adults in The Netherlands","volume":"142","author":"Van Mens","year":"2014","journal-title":"Epidemiol Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2015.11.048_bib0360","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/gerona\/glp012","article-title":"Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries","volume":"64","author":"Santos-Eggimann","year":"2009","journal-title":"J Gerontol A Biol Sci Med Sci"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15016977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15016977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T05:56:22Z","timestamp":1537163782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15016977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0264410X15016977"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.11.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}